(Un-)Known Chances: Emerging Hope for Cancer of Unknown Primary - Highlights from ESMO 2025 and the first International Cancer of Unknown Primary Meeting.
Maximilian Haas, Louisa Hempel, Alwin Krämer, Gerdt Hübner
{"title":"(Un-)Known Chances: Emerging Hope for Cancer of Unknown Primary - Highlights from ESMO 2025 and the first International Cancer of Unknown Primary Meeting.","authors":"Maximilian Haas, Louisa Hempel, Alwin Krämer, Gerdt Hübner","doi":"10.1159/000551434","DOIUrl":null,"url":null,"abstract":"<p><p>Cancer of unknown primary (CUP) accounts for 1-3% of newly diagnosed cancers. For decades, management has relied on empirical platinum-based chemotherapy, which offers a poor prognosis with a median overall survival typically below one year. However, data from the ESMO 2025 Congress and the International Cancer of Unknown Primary Meeting (ICUPM) signal a transformative shift in the field. This review synthesises current and upcoming data on integrative genomic profiling, liquid biopsy-based tissue-of-origin prediction, functional imaging, and tumour-agnostic therapeutic strategies in CUP. Together, these advances support redefining CUP as a molecularly stratifiable disease requiring early comprehensive profiling and multidisciplinary interpretation to improve outcomes.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"1-11"},"PeriodicalIF":1.6000,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Research and Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000551434","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Cancer of unknown primary (CUP) accounts for 1-3% of newly diagnosed cancers. For decades, management has relied on empirical platinum-based chemotherapy, which offers a poor prognosis with a median overall survival typically below one year. However, data from the ESMO 2025 Congress and the International Cancer of Unknown Primary Meeting (ICUPM) signal a transformative shift in the field. This review synthesises current and upcoming data on integrative genomic profiling, liquid biopsy-based tissue-of-origin prediction, functional imaging, and tumour-agnostic therapeutic strategies in CUP. Together, these advances support redefining CUP as a molecularly stratifiable disease requiring early comprehensive profiling and multidisciplinary interpretation to improve outcomes.
期刊介绍：
With the first issue in 2014, the journal ''Onkologie'' has changed its title to ''Oncology Research and Treatment''. By this change, publisher and editor set the scene for the further development of this interdisciplinary journal. The English title makes it clear that the articles are published in English – a logical step for the journal, which is listed in all relevant international databases. For excellent manuscripts, a ''Fast Track'' was introduced: The review is carried out within 2 weeks; after acceptance the papers are published online within 14 days and immediately released as ''Editor’s Choice'' to provide the authors with maximum visibility of their results. Interesting case reports are published in the section ''Novel Insights from Clinical Practice'' which clearly highlights the scientific advances which the report presents.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
